Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus

Summary

This study is expected to demonstrate the anti-diabetic efficacy of 3-months treatment with GFT505 (80 mg/d) on Glycosylated Haemoglobin A1c (HbA1C) and fasting plasma glucose. And to assess the tolerability and safety of once-a-day administrations of oral doses of GFT505 for 12 weeks in patients with type 2 diabetes mellitus.

Timeline

Start

2010-12

Primary completion

2011-06

Completion

2011-06

Drugs

Indications